• Home
  • About Us
  • Testimonials

Testimonials

amh

"The ability to treat the aging eye or the Presbyopic patient with a quick ultra-minimally invasive laser eye therapy holds real promise to making an impact in the quality of life of almost a billion people. Near vision loss of sight is not only a disability and frustrating inconvenience but rather a real ocular health concern. If we can restore normal biomechanical function to the eye organ, perhaps we can potentially even delay cataract formation, and improve eye health and longevity. The potential with LaserACE® should not be underestimated."

AnnMarie Hipsley, DPT, PHD
Founder
Ace Vision Group, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

amh

"My decision on being involved as an investigator with LaserACE® technology is threefold: (1) the ability to restore dynamic accommodation without compromise to the refractive state of the eye; (2) the lack of visual axis compromise; (3) the market potential for such a procedure on emmetropic presbyopes and/or past monofocal IOL patients is immense.  I truly am excited about continuing to pave the way for my patients to see beyond their imagination by using a technology that rejuvenates the eye’s natural power."

Mitchell A. Jackson, MD
JacksonEye
Lake Villa, Illinois
This email address is being protected from spambots. You need JavaScript enabled to view it.

amh

"I am very optimistic about the potential of the LaserACE® Technology for the treatment of so many of us who desire to have our near vision restored to a functional level.  We need a dynamic range of vision to function on a daily basis, without any compromise of distance vision and there is no other procedure available today that can offer this.  This can only occur in a non-corneal based procedure and with this technology; many patients have enjoyed even better distance, without any loss of best corrected vision. Restoring dynamic accommodation is the goal that had been unobtainable before the LaserACE® procedure was founded and this indeed is the most natural way to restore the ability to have near vision without any effect on the visual axis."

Sheri Rowen, MD,
Rowen Vision & Cosmetic Center
Baltimore, MD
This email address is being protected from spambots. You need JavaScript enabled to view it.

amh

"Being the very first PI who executed the LaserACE® human clinical trial, I witnessed  the ability of LaserACE® to make a dramatic improvement in near vision. I am very excited to be a part of the further development of this procedure and the impact that it potentially can have on millions of people in need of such a procedure. It is easy to perform and safe, since it does not touch the optical elements of the eye. Theoretically, combination with other procedures is possible to further augment the effects of the procedure."

Professor David HK Ma, MD, PHD
Chang Gung Memorial Hospital
Taipei, Taiwan
This email address is being protected from spambots. You need JavaScript enabled to view it.

amh

"This is so interesting because it represents a departure from the current thinking for how we achieve depth of focus and treat clinical symptoms of presbyopia. It is a whole new paradigm that offers an approach to treat the actual source of presbyopia and not just the symptoms."

George O. Waring IV, MD, FACS
Medical University of South Carolina /Storm Eye Institute
Charleston, South Carolina
This email address is being protected from spambots. You need JavaScript enabled to view it.
 

amh

"Being invited to participate in the development of novel and timely presbyopia treating technology at such an early stage in its evolution is most humbling as LaserACE® has the opportunity to benefit such a large and growing demographic on a global scale."
 
Steven Silverstein, MD
Silverstein Eye Centers
Kansas City, MO
This email address is being protected from spambots. You need JavaScript enabled to view it.
 

amh

"I believe this technology will not only help us address one of the most prominent conditions that people suffer in their 40’s and beyond, but holds promise to be one of the first procedures to treat the source of the problem of presbyopia while not touching the visual axis”.  The high safety profile makes this procedure an attractive alternative to current presbyopic technologies that have potential to either compromise distance vision or cause unavoidable and unwanted visual disturbances."

William Trattler, MD
Center For Excellence in EyeCare
Miami, Florida
This email address is being protected from spambots. You need JavaScript enabled to view it.

dan goldberg

"LaserACE® improves the dynamic range of vision without risk to the optical elements of the eye(cornea and lens). 'Aging of all ocular structures including both choroid and sclera influence the focusing movement of the lens. Loss of elasticity and movement of the choroid, along with increased rigidity of the sclera progressively limit the reciprocal movements of accommodation. LaserACE® enhances accommodative movement by reversing the rigidity of age, and the target tissue is not in the visual axis."

Daniel B Goldberg MD
Atlantic Eye Physicians
Little Silver, New Jersey
This email address is being protected from spambots. You need JavaScript enabled to view it.

Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.

logomobilesidebar